Why is melanoma so metastatic?

Pigment Cell and Melanoma Research

Volumn 27, Issue 1, 2014, Pages 19-36

  Braeuer, Russell R ^a   Watson, Ian R ^a   Wu, Chang Jiun ^a   Mobley, Aaron K ^a   Kamiya, Takafumi ^a   Shoshan, Einav ^a   Bar Eli, Menashe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Mesenchymal phenotype; Metastasis; Mutations profile; Stemness

Indexed keywords

ANTIGEN; CD146 ANTIGEN;

ANGIOGENESIS; CELL SURFACE; EXOSOME; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; LYMPHANGIOGENESIS; MELANOMA; MELANOMA CELL; MELANOMA METASTASIS; MESENCHYME; METASTATIC MELANOMA; NONHUMAN; PHENOTYPE; REVIEW; TUMOR MICROENVIRONMENT;

ANGIOGENESIS; MESENCHYMAL PHENOTYPE; METASTASIS; MUTATIONS PROFILE; STEMNESS;

ANIMALS; ANTIGENS, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SPECIFICITY;

EID: 84890792445     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12172     Document Type: Review

References (171)

1. Aliotta, J.M., Pereira, M., Johnson, K.W. et al. (2010). Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription. Exp. Hematol. 38, 233-245.
2. Arap, W., Kolonin, M.G., Trepel, M. et al. (2002). Steps toward mapping the human vasculature by phage display. Nat. Med. 8, 121-127.
3. Ataera, H., Hyde, E., Price, K.M., Stoitzner, P., and Ronchese, F. (2011). Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS ONE 6, e17515.
4. Azuma, T., Yao, S., Zhu, G., Flies, A.S., Flies, S.J., and Chen, L. (2008). B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111, 3635-3643.
5. Bailey, C.M., Morrison, J.A., and Kulesa, P.M. (2012). Melanoma revives an embryonic migration program to promote plasticity and invasion. Pigment Cell Melanoma Res. 25, 573-583.
6. Balch, C.M., Gershenwald, J.E., Soong, S.J. et al. (2009). Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206.
7. Bar-Eli, M. (1999). Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67, 12-18.
8. Berger, M.F., Hodis, E., Heffernan, T.P. et al. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506.
9. Bhoumik, A., Ivanov, V., and Ronai, Z. (2001). Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment. Clin. Cancer Res. 7, 331-342.
10. Boni, A., Cogdill, A.P., Dang, P. et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213-5219.
11. Braeuer, R.R., Zigler, M., Villares, G.J., Dobroff, A.S., and Bar-Eli, M. (2011). Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin. Cancer Biol. 21, 83-88.
12. Braeuer, R.R., Shoshan, E., Kamiya, T., and Bar-Eli, M. (2012a). The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res. 25, 592-601.
13. Braeuer, R.R., Zigler, M., Kamiya, T. et al. (2012b). Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res. 72, 5757-5766.
14. Calignano, A., Cirino, G., Meli, R., and Persico, P. (1988). Isolation and identification of platelet-activating factor in UV-irradiated guinea pig skin. J. Pharmacol. Methods 19, 89-91.
15. Carretero, R., Romero, J.M., Ruiz-Cabello, F., Maleno, I., Rodriguez, F., Camacho, F.M., Real, L.M., Garrido, F., and Cabrera, T. (2008). Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 60, 439-447.
16. Castelli, C., Rivoltini, L., Andreola, G., Carrabba, M., Renkvist, N., and Parmiani, G. (2000). T-cell recognition of melanoma-associated antigens. J. Cell. Physiol. 182, 323-331.
17. Cederbom, L., Hall, H., and Ivars, F. (2000). CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur. J. Immunol. 30, 1538-1543.
18. Cianfarani, F., Mastroeni, S., Odorisio, T., Passarelli, F., Cattani, C., Mannooranparampil, T.J., Fortes, C., and Failla, C.M. (2012). Expression of vascular endothelial growth factor-C in primary cutaneous melanoma predicts sentinel lymph node positivity. J. Cutan. Pathol. 39, 826-834.
19. Civenni, G., Walter, A., Kobert, N. et al. (2011). Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 71, 3098-3109.
20. Clemente, C.G., Mihm, M.C. Jr, Bufalino, R., Zurrida, S., Collini, P., and Cascinelli, N. (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303-1310.
21. Cocucci, E., Racchetti, G., and Meldolesi, J. (2009). Shedding microvesicles: artefacts no more. Trends Cell Biol. 19, 43-51.
22. Davis, M.J., Ha, B.H., Holman, E.C., Halaban, R., Schlessinger, J., and Boggon, T.J. (2013). RAC1P29S is a spontaneously activating cancer-associated GTPase. Proc. Natl Acad. Sci. USA 110, 912-917.
23. Demotte, N., Wieers, G., Van Der Smissen, P. et al. (2010). A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 70, 7476-7488.
24. Denton, K.J., Stretch, J.R., Gatter, K.C., and Harris, A.L. (1992). A study of adhesion molecules as markers of progression in malignant melanoma. J. Pathol. 167, 187-191.
25. Dobroff, A.S., Wang, H., Melnikova, V.O., Villares, G.J., Zigler, M., Huang, L., and Bar-Eli, M. (2009). Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J. Biol. Chem. 284, 26194-26206.
26. Dong, H., Strome, S.E., Salomao, D.R. et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800.
27. D'Urso, C.M., Wang, Z.G., Cao, Y., Tatake, R., Zeff, R.A., and Ferrone, S. (1991). Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2 m gene expression. J. Clin. Invest. 87, 284-292.
28. Dvorak, H.F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659.
29. Eken, C., Gasser, O., Zenhaeusern, G., Oehri, I., Hess, C., and Schifferli, J.A. (2008). Polymorphonuclear neutrophil-derived ectosomes interfere with the maturation of monocyte-derived dendritic cells. J. Immunol. 180, 817-824.
30. Elliott, R.L., and Blobe, G.C. (2005). Role of transforming growth factor Beta in human cancer. J. Clin. Oncol. 23, 2078-2093.
31. Ellis, L.M., and Hicklin, D.J. (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591.
32. Emery, C.M., Vijayendran, K.G., Zipser, M.C. et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA 106, 20411-20416.
33. Erhard, H., Rietveld, F.J., Van Altena, M.C., Brocker, E.B., Ruiter, D.J., and De Waal, R.M. (1997). Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res. 7(Suppl 2), S19-S26.
34. Fevrier, B., and Raposo, G. (2004). Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 16, 415-421.
35. Frade, R., Rodrigues-Lima, F., Huang, S., Xie, K., Guillaume, N., and Bar-Eli, M. (1998). Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res. 58, 2733-2736.
36. Frederick, D.T., Piris, A., Cogdill, A.P. et al. (2013). BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225-1231.
37. Furney, S.J., Turajlic, S., Stamp, G. et al. (2013). Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J. Pathol. 230, 261-269.
38. Galon, J., Costes, A., Sanchez-Cabo, F. et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964.
39. Garibyan, L., and Fisher, D.E. (2010). How sunlight causes melanoma. Curr. Oncol. Rep. 12, 319-326.
40. Garrido, F., Cabrera, T., and Aptsiauri, N. (2010). "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. International journal of cancer. Int. J. Cancer 127, 249-256.
41. Gershenwald, J.E., Sumner, W., Calderone, T., Wang, Z., Huang, S., and Bar-Eli, M. (2001). Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene 20, 3363-3375.
42. Goel, V., Vartanian, O., Bartolo, A., Hakim, L., Maria Ferraro, A., Isella, V., Appollonio, I., Drei, S., and Nichelli, P. (2012). Lesions to right prefrontal cortex impair real-world planning through prematurecommitments. Neuropsychologia 51, 713-724.
43. Grossmann, A.H., Yoo, J.H., Clancy, J. et al. (2013). The small GTPase ARF6 stimulates beta-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci. Signal. 6, ra14.
44. Gupta, P.B., Kuperwasser, C., Brunet, J.P., Ramaswamy, S., Kuo, W.L., Gray, J.W., Naber, S.P., and Weinberg, R.A. (2005). The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat. Genet. 37, 1047-1054.
45. Haass, N.K., Smalley, K.S., Li, L., and Herlyn, M. (2005). Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 18, 150-159.
46. Haddow, A. (1972). Molecular repair, wound healing, and carcinogenesis: tumor production a possible overhealing? Adv. Cancer Res. 16, 181-234.
47. Hall, H., Carbonetto, S., and Schachner, M. (1997). L1/HNK-1 carbohydrate- and beta 1 integrin-dependent neural cell adhesion to laminin-1. J. Neurochem. 68, 544-553.
48. Harbour, J.W., Onken, M.D., Roberson, E.D., Duan, S., Cao, L., Worley, L.A., Council, M.L., Matatall, K.A., Helms, C., and Bowcock, A.M. (2010). Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410-1413.
49. Hendrix, M.J., Seftor, E.A., Meltzer, P.S., Gardner, L.M., Hess, A.R., Kirschmann, D.A., Schatteman, G.C., and Seftor, R.E. (2001). Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl Acad. Sci. USA 98, 8018-8023.
50. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
51. Hoek, K.S., and Goding, C.R. (2010). Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 23, 746-759.
52. Hood, J.L., San, R.S., and Wickline, S.A. (2011). Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71, 3792-3801.
53. Horsman, D.E., Sroka, H., Rootman, J., and White, V.A. (1990). Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genet. Cytogenet. 45, 249-253.
54. Hortsch, M. (1996). The L1 family of neural cell adhesion molecules: old proteins performing new tricks. Neuron 17, 587-593.
55. Hsu, M.Y., Wheelock, M.J., Johnson, K.R., and Herlyn, M. (1996). Shifts in cadherin profiles between human normal melanocytes and melanomas. J. Investig. Dermatol. Symp. Proc. 1, 188-194.
56. International Cancer Genome Consortium, Hudson, T.J., Anderson, W. et al. (2010). International network of cancer genome projects. Nature 464, 993-998.
57. Jacobs, J.F., Nierkens, S., Figdor, C.G., De Vries, I.J., and Adema, G.J. (2012). Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 13, e32-e42.
58. Jean, D., Bar-Eli, M., Huang, S., Xie, K., Rodrigues-Lima, F., Hermann, J., and Frade, R. (1996). A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res. 56, 254-258.
59. Joyce, J.A., and Pollard, J.W. (2009). Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239-252.
60. Kaplan, R.N., Riba, R.D., Zacharoulis, S. et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827.
61. Karjalainen, J.M., Kellokoski, J.K., Eskelinen, M.J., Alhava, E.M., and Kosma, V.M. (1998). Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J. Clin. Oncol. 16, 3584-3591.
62. Kharaziha, P., Ceder, S., Li, Q., and Panaretakis, T. (2012). Tumor cell-derived exosomes: a message in a bottle. Biochim. Biophys. Acta 1826, 103-111.
63. Kimpfler, S., Sevko, A., Ring, S., Falk, C., Osen, W., Frank, K., Kato, M., Mahnke, K., Schadendorf, D., and Umansky, V. (2009). Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J. Immunol. 183, 6330-6337.
64. Kirkwood, J.M., Tarhini, A.A., Panelli, M.C., Moschos, S.J., Zarour, H.M., Butterfield, L.H., and Gogas, H.J. (2008). Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26, 3445-3455.
65. Kowitz, A., Kadmon, G., Eckert, M., Schirrmacher, V., Schachner, M., and Altevogt, P. (1992). Expression and function of the neural cell adhesion molecule L1 in mouse leukocytes. Eur. J. Immunol. 22, 1199-1205.
66. Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
67. Krishnan, V., Bane, S.M., Kawle, P.D., Naresh, K.N., and Kalraiya, R.D. (2005). Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin. Exp. Metastasis 22, 11-24.
68. Kujat, R., Miragall, F., Krause, D., Dermietzel, R., and Wrobel, K.H. (1995). Immunolocalization of the neural cell adhesion molecule L1 in non-proliferating epithelial cells of the male urogenital tract. Histochem. Cell Biol. 103, 311-321.
69. Lampen, M.H., and Van Hall, T. (2011). Strategies to counteract MHC-I defects in tumors. Curr. Opin. Immunol. 23, 293-298.
70. Langley, R.R., and Fidler, I.J. (2011). The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. International journal of cancer. Int. J. Cancer 128, 2527-2535.
71. Le Poole, I.C., Van Den Wijngaard, R.M., Westerhof, W., Dormans, J.A., Van Den Berg, F.M., Verkruisen, R.P., Dingemans, K.P., and Das, P.K. (1994). Organotypic culture of human skin to study melanocyte migration. Pigment Cell Res. 7, 33-43.
72. Lee, S., Chen, T.T., Barber, C.L., Jordan, M.C., Murdock, J., Desai, S., Ferrara, N., Nagy, A., Roos, K.P., and Iruela-Arispe, M.L. (2007). Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703.
73. Lehmann, J.M., Holzmann, B., Breitbart, E.W., Schmiegelow, P., Riethmuller, G., and Johnson, J.P. (1987). Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113 000 and a protein with a molecular weight of 76 000. Cancer Res. 47, 841-845.
74. Leung, A.M., Hari, D.M., and Morton, D.L. (2012). Surgery for distant melanoma metastasis. Cancer J. 18, 176-184.
75. Levstik, M., Wong, P., Greanya, E.D., and Yoshida, E.M. (2011). The role of hepatitis B immunoglobulin in hepatitis B related liver transplantation: Canadian Transplant Centre Position Paper. Ann. Hepatol. 10, 441-444.
76. Li, G., Satyamoorthy, K., and Herlyn, M. (2001). N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 61, 3819-3825.
77. Li, A., Dubey, S., Varney, M.L., Dave, B.J., and Singh, R.K. (2003). IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 170, 3369-3376.
78. Li, M.O., Wan, Y.Y., Sanjabi, S., Robertson, A.K., and Flavell, R.A. (2006). Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24, 99-146.
79. Lin, Q., Balasubramanian, K., Fan, D., Kim, S.J., Guo, L., Wang, H., Bar-Eli, M., Aldape, K.D., and Fidler, I.J. (2010). Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12, 748-754.
80. Liu, F.T., and Rabinovich, G.A. (2005). Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29-41.
81. Maertens, O., Johnson, B., Hollstein, P. et al. (2013). Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 3, 338-349.
82. Malumbres, M., and Barbacid, M. (2003). RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459-465.
83. Maniotis, A.J., Folberg, R., Hess, A., Seftor, E.A., Gardner, L.M., Pe'er, J., Trent, J.M., Meltzer, P.S., and Hendrix, M.J. (1999). Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739-752.
84. Margolin, K., Ernstoff, M.S., Hamid, O. et al. (2012). Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459-465.
85. McGary, E.C., Lev, D.C., and Bar-Eli, M. (2002). Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol. Ther. 1, 459-465.
86. Melnikova, V.O., and Bar-Eli, M. (2006). Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res. 19, 395-405.
87. Melnikova, V., and Bar-Eli, M. (2007). Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev. 26, 359-371.
88. Melnikova, V.O., and Bar-Eli, M. (2008). Transcriptional control of the melanoma malignant phenotype. Cancer Biol. Ther. 7, 997-1003.
89. Melnikova, V.O., and Bar-Eli, M. (2009). Inflammation and melanoma metastasis. Pigment Cell Melanoma Res. 22, 257-267.
90. Melnikova, V.O., Balasubramanian, K., Villares, G.J. et al. (2009). Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J. Biol. Chem. 284, 28845-28855.
91. Melnikova, V.O., Dobroff, A.S., Zigler, M., Villares, G.J., Braeuer, R.R., Wang, H., Huang, L., and Bar-Eli, M. (2010). CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS ONE 5, e12452.
92. Mihic-Probst, D., Ikenberg, K., Tinguely, M., Schraml, P., Behnke, S., Seifert, B., Civenni, G., Sommer, L., Moch, H., and Dummer, R. (2012). Tumor cell plasticity and angiogenesis in human melanomas. PLoS ONE 7, e33571.
93. Mills, L., Tellez, C., Huang, S., Baker, C., McCarty, M., Green, L., Gudas, J.M., Feng, X., and Bar-Eli, M. (2002). Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 62, 5106-5114.
94. Mobley, A.K., Braeuer, R.R., Kamiya, T., Shoshan, E., and Bar-Eli, M. (2012). Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev. 31, 621-632.
95. Montgomery, A.M., Becker, J.C., Siu, C.H., Lemmon, V.P., Cheresh, D.A., Pancook, J.D., Zhao, X., and Reisfeld, R.A. (1996). Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J. Cell Biol. 132, 475-485.
96. Moretti, S., Pinzi, C., Spallanzani, A., Berti, E., Chiarugi, A., Mazzoli, S., Fabiani, M., Vallecchi, C., and Herlyn, M. (1999). Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. International journal of cancer. Int. J. Cancer 84, 160-168.
97. Mourad-Zeidan, A.A., Melnikova, V.O., Wang, H., Raz, A., and Bar-Eli, M. (2008). Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am. J. Pathol. 173, 1839-1852.
98. Mu, H., Calderone, T.L., Davies, M.A., Prieto, V.G., Wang, H., Mills, G.B., Bar-Eli, M., and Gershenwald, J.E. (2012). Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am. J. Pathol. 180, 2170-2181.
99. Nikolaev, S.I., Rimoldi, D., Iseli, C. et al. (2012). Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44, 133-139.
100. Nizar, S., Meyer, B., Galustian, C., Kumar, D., and Dalgleish, A. (2010). T regulatory cells, the evolution of targeted immunotherapy. Biochim. Biophys. Acta 1806, 7-17.
101. Ofori-Acquah, S.F., and King, J.A. (2008). Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl. Res. 151, 122-128.
102. Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, 98-101.
103. Pancook, J.D., Reisfeld, R.A., Varki, N., Vitiello, A., Fox, R.I., and Montgomery, A.M. (1997). Expression and regulation of the neural cell adhesion molecule L1 on human cells of myelomonocytic and lymphoid origin. J. Immunol. 158, 4413-4421.
104. Park, E.S., Kim, S.J., Kim, S.W. et al. (2011). Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc. Natl Acad. Sci. USA 108, 17456-17461.
105. Pei, Y., Barber, L.A., Murphy, R.C., Johnson, C.A., Kelley, S.W., Dy, L.C., Fertel, R.H., Nguyen, T.M., Williams, D.A., and Travers, J.B. (1998). Activation of the epidermal platelet-activating factor receptor results in cytokine and cyclooxygenase-2 biosynthesis. J. Immunol. 161, 1954-1961.
106. Peinado, H., Lavotshkin, S., and Lyden, D. (2011). The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 21, 139-146.
107. Peinado, H., Aleckovic, M., Lavotshkin, S. et al. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883-891.
108. Postow, M.A., Harding, J., and Wolchok, J.D. (2012). Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J. 18, 153-159.
109. Prescher, G., Bornfeld, N., and Becher, R. (1990). Nonrandom chromosomal abnormalities in primary uveal melanoma. J. Natl Cancer Inst. 82, 1765-1769.
110. Prieto, V.G., Mourad-Zeidan, A.A., Melnikova, V. et al. (2006). Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin. Cancer Res. 12, 6709-6715.
111. Ptaszynska, M.M., Pendrak, M.L., Stracke, M.L., and Roberts, D.D. (2010). Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol. Cancer Res. 8, 309-321.
112. Puches, R., Smolle, J., Rieger, E., Soyer, H.P., and Kerl, H. (1991). Expression of cytoskeletal components in melanocytic skin lesions. An immunohistochemical study. Am. J. Dermatopathol. 13, 137-144.
113. Qi, J., Chen, N., Wang, J., and Siu, C.H. (2005). Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol. Biol. Cell 16, 4386-4397.
114. Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., and Morrison, S.J. (2008). Efficient tumour formation by single human melanoma cells. Nature 456, 593-598.
115. Quintana, E., Piskounova, E., Shackleton, M., Weinberg, D., Eskiocak, U., Fullen, D.R., Johnson, T.M., and Morrison, S.J. (2012). Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci. Transl. Med. 4, 159ra149.
116. Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A., and Ratajczak, M.Z. (2006). Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 20, 1487-1495.
117. Reed, J.A., McNutt, N.S., and Albino, A.P. (1994). Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am. J. Pathol. 144, 329-336.
118. Reid, A.L., Millward, M., Pearce, R. et al. (2013). Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br. J. Dermatol. 168, 85-92.
119. Robert, C., Thomas, L., Bondarenko, I. et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526.
120. Rubtsov, Y.P., and Rudensky, A.Y. (2007). TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat. Rev. Immunol. 7, 443-453.
121. Rummelt, V., Folberg, R., Rummelt, C., Gruman, L.M., Hwang, T., Woolson, R.F., Yi, H., and Naumann, G.O. (1994). Microcirculation architecture of melanocytic nevi and malignant melanomas of the ciliary body and choroid. A comparative histopathologic and ultrastructural study. Ophthalmology 101, 718-727.
122. Sakaguchi, S., Yamaguchi, T., Nomura, T., and Ono, M. (2008). Regulatory T cells and immune tolerance. Cell 133, 775-787.
123. Salven, P., Heikkila, P., and Joensuu, H. (1997). Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br. J. Cancer 76, 930-934.
124. Sandig, M., Voura, E.B., Kalnins, V.I., and Siu, C.H. (1997). Role of cadherins in the transendothelial migration of melanoma cells in culture. Cell Motil. Cytoskelet. 38, 351-364.
125. Scott, G.A., and Haake, A.R. (1991). Keratinocytes regulate melanocyte number in human fetal and neonatal skin equivalents. J. Invest. Dermatol. 97, 776-781.
126. Scott, K.L., Nogueira, C., Heffernan, T.P. et al. (2011). Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell 20, 92-103.
127. Seliger, B., Ritz, U., Abele, R., Bock, M., Tampe, R., Sutter, G., Drexler, I., Huber, C., and Ferrone, S. (2001). Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 61, 8647-8650.
128. Serra, P., Amrani, A., Yamanouchi, J., Han, B., Thiessen, S., Utsugi, T., Verdaguer, J., and Santamaria, P. (2003). CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity 19, 877-889.
129. Sethi, N., and Kang, Y. (2011). Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat. Rev. Cancer 11, 735-748.
130. Shah, K.V., Chien, A.J., Yee, C., and Moon, R.T. (2008). CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J. Invest. Dermatol. 128, 2870-2879.
131. Shih, I.M., Elder, D.E., Hsu, M.Y., and Herlyn, M. (1994). Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am. J. Pathol. 145, 837-845.
132. Shihmanter, E., Weisman, Y., and Lipkind, M. (1995). Isolation of Yucaipa virus. Vet. Rec. 137, 276.
133. Shirakawa, K., Kobayashi, H., Sobajima, J., Hashimoto, D., Shimizu, A., and Wakasugi, H. (2003). Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res. 5, 136-139.
134. Si, S.P., Tsou, H.C., Lee, X., and Peacocke, M. (1993). Cultured human melanocytes express the intermediate filament vimentin. J. Invest. Dermatol. 101, 383-386.
135. Siegel, R., Naishadham, D., and Jemal, A. (2013). Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30.
136. Singh, S., Varney, M., and Singh, R.K. (2009). Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res. 69, 411-415.
137. Sisley, K., Rennie, I.G., Cottam, D.W., Potter, A.M., Potter, C.W., and Rees, R.C. (1990). Cytogenetic findings in six posterior uveal melanomas: involvement of chromosomes 3, 6, and 8. Genes Chromosom. Cancer 2, 205-209.
138. Stalin, J., Harhouri, K., Hubert, L. et al. (2013). Soluble melanoma cell adhesion molecule (sMCAM/sCD146) promotes angiogenic effects on endothelial progenitor cells through angiomotin. J. Biol. Chem. 288, 8991-9000.
139. Stark, M.S., Woods, S.L., Gartside, M.G. et al. (2012). Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 44, 165-169.
140. Stoitzner, P., Green, L.K., Jung, J.Y., Price, K.M., Atarea, H., Kivell, B., and Ronchese, F. (2008). Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol. Immunother. 57, 1665-1673.
141. Stracke, M.L., Krutzsch, H.C., Unsworth, E.J., Arestad, A., Cioce, V., Schiffmann, E., and Liotta, L.A. (1992). Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 267, 2524-2529.
142. Sumimoto, H., Imabayashi, F., Iwata, T., and Kawakami, Y. (2006). The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651-1656.
143. Swart, G.W., Lunter, P.C., Kilsdonk, J.W., and Kempen, L.C. (2005). Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev. 24, 223-236.
144. Thery, C., Zitvogel, L., and Amigorena, S. (2002). Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2, 569-579.
145. Thies, A., Schachner, M., Moll, I., Berger, J., Schulze, H.J., Brunner, G., and Schumacher, U. (2002). Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur. J. Cancer 38, 1708-1716.
146. Thingnes, J., Lavelle, T.J., Hovig, E., and Omholt, S.W. (2012). Understanding the melanocyte distribution in human epidermis: an agent-based computational model approach. PLoS ONE 7, e40377.
147. Thompson, E.D., Enriquez, H.L., Fu, Y.X., and Engelhard, V.H. (2010). Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 207, 1791-1804.
148. Topalian, S.L., Hodi, F.S., Brahmer, J.R. et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
149. Valyi-Nagy, I.T., Hirka, G., Jensen, P.J., Shih, I.M., Juhasz, I., and Herlyn, M. (1993). Undifferentiated keratinocytes control growth, morphology, and antigen expression of normal melanocytes through cell-cell contact. Lab. Invest. 69, 152-159.
150. Van Kempen, L.C., Van Den Oord, J.J., Van Muijen, G.N., Weidle, U.H., Bloemers, H.P., and Swart, G.W. (2000). Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am. J. Pathol. 156, 769-774.
151. Van Kilsdonk, J.W., Wilting, R.H., Bergers, M., Van Muijen, G.N., Schalkwijk, J., Van Kempen, L.C., and Swart, G.W. (2008). Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res. 68, 3671-3679.
152. Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'Brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602.
153. Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B. et al. (2010). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191-2199.
154. Varney, M.L., Johansson, S.L., and Singh, R.K. (2006). Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am. J. Clin. Pathol. 125, 209-216.
155. Vartanian, A.A. (2012). Signaling pathways in tumor vasculogenic mimicry. Biochemistry (Mosc) 77, 1044-1055.
156. Villares, G.J., Zigler, M., Wang, H. et al. (2008). Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 68, 9078-9086.
157. Villares, G.J., Dobroff, A.S., Wang, H., Zigler, M., Melnikova, V.O., Huang, L., and Bar-Eli, M. (2009). Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. Cancer Res. 69, 6730-6737.
158. Villares, G.J., Zigler, M., Dobroff, A.S., Wang, H., Song, R., Melnikova, V.O., Huang, L., Braeuer, R.R., and Bar-Eli, M. (2011). Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. Proc. Natl Acad. Sci. USA 108, 626-631.
159. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr, and Kinzler, K.W. (2013). Cancer genome landscapes. Science 339, 1546-1558.
160. Voura, E.B., Sandig, M., and Siu, C.H. (1998). Cell-cell interactions during transendothelial migration of tumor cells. Microsc. Res. Tech. 43, 265-275.
161. Voura, E.B., Ramjeesingh, R.A., Montgomery, A.M., and Siu, C.H. (2001). Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol. Biol. Cell 12, 2699-2710.
162. Walterscheid, J.P., Ullrich, S.E., and Nghiem, D.X. (2002). Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J. Exp. Med. 195, 171-179.
163. Wardwell-Ozgo, J., Dogruluk, T., Gifford, A., Zhang, Y., Heffernan, T.P., Van Doorn, R., Creighton, C.J., Chin, L., and Scott, K.L. (2013). HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene 1-10.
164. Webster, M.R., and Weeraratna, A.T. (2013). A Wnt-er migration: the confusing role of beta-catenin in melanoma metastasis. Sci. Signal. 6, pe11.
165. Wei, X., Walia, V., Lin, J.C. et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446.
166. Wilmott, J.S., Long, G.V., Howle, J.R., Haydu, L.E., Sharma, R.N., Thompson, J.F., Kefford, R.F., Hersey, P., and Scolyer, R.A. (2012). Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18, 1386-1394.
167. Worley, L.A., Onken, M.D., Person, E., Robirds, D., Branson, J., Char, D.H., Perry, A., and Harbour, J.W. (2007). Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin. Cancer Res. 13, 1466-1471.
168. Xie, S., Luca, M., Huang, S., Gutman, M., Reich, R., Johnson, J.P., and Bar-Eli, M. (1997). Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res. 57, 2295-2303.
169. Yates, L.R., and Campbell, P.J. (2012). Evolution of the cancer genome. Nat. Rev. Genet. 13, 795-806.
170. Zaidi, M.R., Davis, S., Noonan, F.P. et al. (2011). Interferon-gamma links ultraviolet radiation to melanomagenesis in mice. Nature 469, 548-553.
171. Zigler, M., Villares, G.J., Dobroff, A.S. et al. (2011). Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression. Cancer Res. 71, 3494-3504.